Prestige BioPharma Limited
Biopharmaceutical company developing antibody therapeutics and biosimilars.
950210 | KO
Overview
Corporate Details
- ISIN(s):
- KR8702070002
- LEI:
- Country:
- Singapore
- Address:
- 21 BIOPOLIS ROAD #04-24 NUCLEOS, SINGAPORE
- Website:
- https://prestigebiopharma.com/
- Sector:
- Manufacturing
Description
Prestige BioPharma Limited is a biopharmaceutical company specializing in the discovery, development, and commercialization of antibody-based therapeutics. The company's portfolio is centered on two primary areas: the development of high-quality biosimilars and the creation of innovative, first-in-class antibody drugs. Its operations encompass the full drug development lifecycle, including preclinical and clinical research, alongside Chemistry, Manufacturing, and Controls (CMC) activities. Prestige BioPharma maintains a diverse pipeline of drug candidates in various stages of development, focusing on advancing biopharmaceutical technologies to provide novel therapeutic solutions for patients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-09-19 00:00 |
감사보고서제출
|
Korean | 21.8 KB | ||
| 2025-09-19 00:00 |
사업보고서 (2025.06)
|
Korean | 3.7 MB | ||
| 2025-09-16 00:00 |
[기재정정]단일판매ㆍ공급계약체결
|
Korean | 12.8 KB | ||
| 2025-09-11 00:00 |
[기재정정]주주총회소집결의
|
Korean | 17.3 KB | ||
| 2025-09-11 00:00 |
주주총회소집공고
|
Korean | 136.7 KB | ||
| 2025-09-09 00:00 |
주주총회소집결의
|
Korean | 9.5 KB | ||
| 2025-08-18 00:00 |
단일판매ㆍ공급계약체결
|
Korean | 8.6 KB | ||
| 2025-08-13 00:00 |
매출액또는손익구조30%(대규모법인은15%)이상변경
|
Korean | 19.1 KB | ||
| 2025-07-31 00:00 |
[기재정정]투자판단관련주요경영사항 (특허권 취득)
|
Korean | 15.7 KB | ||
| 2025-06-13 00:00 |
기타경영사항(자율공시) (제10기 정기주주총회 권리주주 확정을 위한 증권예탁증권 기준일 설정 공고)
|
Korean | 4.4 KB | ||
| 2025-05-30 00:00 |
기업지배구조보고서공시
|
Korean | 934.4 KB | ||
| 2025-05-30 00:00 |
분기보고서 (2025.03)
|
Korean | 1.6 MB | ||
| 2025-05-26 00:00 |
투자판단관련주요경영사항 (Tuznue (HD201,Trastuzumab 바이오시밀러) 판매에 대한 라이선스 및 공급 계…
|
Korean | 8.9 KB | ||
| 2025-02-28 00:00 |
반기보고서 (2024.12)
|
Korean | 1.5 MB | ||
| 2025-02-13 00:00 |
주식등의대량보유상황보고서(약식)
|
Korean | 72.7 KB |
Automate Your Workflow. Get a real-time feed of all Prestige BioPharma Limited filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Prestige BioPharma Limited
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Prestige BioPharma Limited via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
